Milestone for Calliditas as FDA grants accelerated approval of TARPEYO™
Our portfolio company Calliditas Therapeutics reached a major milstone yesterday with its accelerated FDA approval of Tarpeyo™, a novel therapy indicated for patients with nephropathy. Industrifonden was the first institutional venture investor in Calliditas backing its mission to bring novel therapies to patients with high unmet needs in renal disease. This landmark achievement will bring a novel therapy in Tarpeyo™ to market in the US for a severe patient population with deterioration of kidney function, so called IgA nephrophaty. Calliditas Therapeutics listed successfully on NASDAQ Stockholm in 2018 and underwent a dual-listing on NASDAQ US in June 2020. We congratulate the entire Calliditas team lead by René Lucander and are glad to support our mission to back lifesciences companies bringing novel therapies to patients with severe health conditions and high unmet need for new therapies.
The press release from Calliditas Therapeutics can be read here.
/Patrik Sobocki, Investment Director, on behalf of the entire team at Industrifonden